Hepion Pharmaceuticals Files Q2 2024 10-Q

TL;DR

Hepion Pharma dropped its Q2 10-Q. Check financials and biz updates.

AI Summary

Hepion Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational highlights from the second quarter of 2024 are detailed within the filing.

Why It Matters

This filing provides investors with crucial financial and operational data for Hepion Pharmaceuticals, enabling them to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Hepion is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 20240813 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Hepion Pharmaceuticals, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240813 (date) — Filing date
• ContraVir Pharmaceuticals, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share HEPA The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 1238KB
• ex31-1.htm (EX-31.1) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• logo_001.jpg (GRAPHIC) — 8KB
• 0001493152-24-031582.txt ( ) — 6082KB
• hepa-20240630.xsd (EX-101.SCH) — 35KB
• hepa-20240630_cal.xml (EX-101.CAL) — 48KB
• hepa-20240630_def.xml (EX-101.DEF) — 199KB
• hepa-20240630_lab.xml (EX-101.LAB) — 355KB
• hepa-20240630_pre.xml (EX-101.PRE) — 312KB
• form10-q_htm.xml (XML) — 996KB

SIGNATURES

SIGNATURES 30 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited consolidated financial statements as of and for the year ended December 31, 2023 contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 16, 2024, as well as under Item 1A . Risk Factors within this Form 10-Q. These factors include the uncertainties associated with: our ability to successfully consummate the proposed merger, or the Merger with Pharma Two B Ltd., or Pharma Two B, or any strategic transaction that we may consummate in the future; our anticipated net cash balance and expectations regarding relative ownership percentages in the combined company following consummation of the Merger; our ability to realize the anticipated benefits of the Merger and our ability to manage the risks of the proposed Merger; the effects that the pen

View Full Filing

View this 10-Q filing on SEC EDGAR